HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound From The Shanghai Institute Of Materia Medica
HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound From The Shanghai Institute Of Materia Medica
San Diego, USA and Shanghai, China – October 2, 2007 — HUYA Bioscience International (HUYA), a rapidly expanding biopharmaceutical company focused on the development of key disease-fighting drugs sourced from China, announced today that it has licensed a novel clinical stage anti-arrhythmic compound from the prestigious Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences.